-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
New drug R&D is characterized by high risk, high investment, and long R&D cycle.
The emergence of AI pharmaceutical technology not only greatly improves the efficiency and success rate of drug R&D, but also effectively reduces the R&D cost and trial-and-error cost of pharmaceutical companies, allowing the pharmaceutical industry to see new dawn
.
2020 is known as the first year of the AI pharmacy outbreak in the industry, and financing events continue to increase
.
According to incomplete statistics in the industry, in 2020, a total of 12 financing events will occur, with a total amount exceeding 2.
7 billion yuan, an increase of about 10 times year-on-year; in 2021, the entire AI pharmaceutical track will continue to accelerate, with a total of 77 cases in the global AI pharmaceutical field throughout the year For financing events, the cumulative financing amount is about 29.
073 billion yuan, an increase of 152% compared to 2020
.
Not only overseas, the domestic AI pharmaceutical financing boom is also on the rise.
In 2021, there will be 34 financing events in the domestic AI pharmaceutical field, with a total financing amount exceeding 8 billion yuan
.
Entering 2022, this track is advancing by leaps and bounds.
In the first quarter of 2022, there will be more than 10 new financings, involving Xihu Omi, Xinhua Bio, Lemang Bio, Shenshi Technology, Yudao Bio, Yiyao Technology, and Kehui Zhiyao.
and other enterprises
.
Judging from the new financing events in the first quarter, many financings exceeded 100 million yuan.
For example, Kehui Zhiyao, the company mainly focuses on innovative drug research and development, and is committed to becoming an AI-driven R&D innovative pharmaceutical company.
Oriented to explore innovative treatments in areas with huge unmet medical needs such as neurology, autoimmunity, and tumors
.
On March 31, the company announced the completion of a Pre A+ round of financing of more than 100 million yuan, led by Jianyi Capital (formerly Sinopharm Capital), and continued to be supported by funds such as old shareholders Honghui Fund, Bopu Capital and Shanxing Capital
.
This round of financing will be used for the construction of an AI platform for new drug research and development, pipeline promotion and expansion, as well as company operations and international business development
.
Another example, West Lake Omi, a company dedicated to the development and application of multi-omics technologies based on protein profiling
.
On January 13, the company announced the completion of several hundred million yuan of Pre-A round of financing.
This round of financing was jointly led by Yifeng Capital and old shareholder Hillhouse Ventures, followed by Powerfang Capital, old shareholder Gaorong Capital and Westlake Venture Capital.
The investment and financing funds will continue to advance the research and development of protein profiling-driven in vitro diagnostic (IVD) products and AI pharmaceutical products
.
Xinhua Bio also announced in early January that it had completed a RMB 100 million financing
.
This round of financing was led by Matrix Partners and joined by Sequoia China and the company’s existing investor Danlu Capital
.
According to public information, Xinhua Bio is an AI-driven macromolecule drug research and development company.
The company team has deep macromolecule drug research and development experience and engineering development data advantages
.
Its innovative target discovery platform, antibody structure and engineering cutting-edge algorithm platform have achieved technological breakthroughs in cross-generation upgrades
.
In addition, judging from the financing situation of AI pharmaceutical companies in previous years, young companies including Jingtai Technology, Insilicon Intelligence, and Shenshi Technology are all "darlings" of capital
.
Among them, Jingtai Technology, which was established in 2015, has completed a financing of about 5.
096 billion yuan so far, setting a new record for the amount of financing in the global AI pharmaceutical field, with a total valuation of more than 13 billion yuan
.
Insilicon is the first in the world to use AI to discover a new mechanism of preclinical candidate compounds for the treatment of idiopathic pulmonary fibrosis (IPF), which greatly improves the speed of new drug development and reduces costs.
A total of 6 rounds of financing have been completed, with a total amount exceeding US$300 million
.
It is worth mentioning that although the continuous entry of capital is conducive to the development of AI pharmaceuticals, the AI pharmaceutical industry is still in the development stage, and there are problems such as scarcity of high-end talents, lack of data and occlusion in the field
.
So far, no new drug discovered by AI has been officially launched, and the road to AI pharmaceuticals in the future is still relatively long
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The emergence of AI pharmaceutical technology not only greatly improves the efficiency and success rate of drug R&D, but also effectively reduces the R&D cost and trial-and-error cost of pharmaceutical companies, allowing the pharmaceutical industry to see new dawn
.
2020 is known as the first year of the AI pharmacy outbreak in the industry, and financing events continue to increase
.
According to incomplete statistics in the industry, in 2020, a total of 12 financing events will occur, with a total amount exceeding 2.
7 billion yuan, an increase of about 10 times year-on-year; in 2021, the entire AI pharmaceutical track will continue to accelerate, with a total of 77 cases in the global AI pharmaceutical field throughout the year For financing events, the cumulative financing amount is about 29.
073 billion yuan, an increase of 152% compared to 2020
.
Not only overseas, the domestic AI pharmaceutical financing boom is also on the rise.
In 2021, there will be 34 financing events in the domestic AI pharmaceutical field, with a total financing amount exceeding 8 billion yuan
.
Entering 2022, this track is advancing by leaps and bounds.
In the first quarter of 2022, there will be more than 10 new financings, involving Xihu Omi, Xinhua Bio, Lemang Bio, Shenshi Technology, Yudao Bio, Yiyao Technology, and Kehui Zhiyao.
and other enterprises
.
Judging from the new financing events in the first quarter, many financings exceeded 100 million yuan.
For example, Kehui Zhiyao, the company mainly focuses on innovative drug research and development, and is committed to becoming an AI-driven R&D innovative pharmaceutical company.
Oriented to explore innovative treatments in areas with huge unmet medical needs such as neurology, autoimmunity, and tumors
.
On March 31, the company announced the completion of a Pre A+ round of financing of more than 100 million yuan, led by Jianyi Capital (formerly Sinopharm Capital), and continued to be supported by funds such as old shareholders Honghui Fund, Bopu Capital and Shanxing Capital
.
This round of financing will be used for the construction of an AI platform for new drug research and development, pipeline promotion and expansion, as well as company operations and international business development
.
Another example, West Lake Omi, a company dedicated to the development and application of multi-omics technologies based on protein profiling
.
On January 13, the company announced the completion of several hundred million yuan of Pre-A round of financing.
This round of financing was jointly led by Yifeng Capital and old shareholder Hillhouse Ventures, followed by Powerfang Capital, old shareholder Gaorong Capital and Westlake Venture Capital.
The investment and financing funds will continue to advance the research and development of protein profiling-driven in vitro diagnostic (IVD) products and AI pharmaceutical products
.
Xinhua Bio also announced in early January that it had completed a RMB 100 million financing
.
This round of financing was led by Matrix Partners and joined by Sequoia China and the company’s existing investor Danlu Capital
.
According to public information, Xinhua Bio is an AI-driven macromolecule drug research and development company.
The company team has deep macromolecule drug research and development experience and engineering development data advantages
.
Its innovative target discovery platform, antibody structure and engineering cutting-edge algorithm platform have achieved technological breakthroughs in cross-generation upgrades
.
In addition, judging from the financing situation of AI pharmaceutical companies in previous years, young companies including Jingtai Technology, Insilicon Intelligence, and Shenshi Technology are all "darlings" of capital
.
Among them, Jingtai Technology, which was established in 2015, has completed a financing of about 5.
096 billion yuan so far, setting a new record for the amount of financing in the global AI pharmaceutical field, with a total valuation of more than 13 billion yuan
.
Insilicon is the first in the world to use AI to discover a new mechanism of preclinical candidate compounds for the treatment of idiopathic pulmonary fibrosis (IPF), which greatly improves the speed of new drug development and reduces costs.
A total of 6 rounds of financing have been completed, with a total amount exceeding US$300 million
.
It is worth mentioning that although the continuous entry of capital is conducive to the development of AI pharmaceuticals, the AI pharmaceutical industry is still in the development stage, and there are problems such as scarcity of high-end talents, lack of data and occlusion in the field
.
So far, no new drug discovered by AI has been officially launched, and the road to AI pharmaceuticals in the future is still relatively long
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
